{"prompt": "['5.2.11 Case Review', 'The Principal Investigator, Mark Buyyounouski, MD and his designee(s) will perform', 'ongoing remote RT Quality Assurance Review after complete data in TRIAD for cases', 'enrolled has been received at IROC Philadelphia-RT.', '5.3', 'General Concomitant Medication and Supportive Care Guidelines', '5.3.1', 'Permitted Supportive/Ancillary Care and Concomitant Medications', 'All supportive therapy for optimal medical care will be given during the study period at', 'the discretion of the attending physician(s) within the parameters of the protocol and', \"documented on each site's source documents as concomitant medication.\", 'Anticonvulsants', 'Antiemetics', 'Anticoagulants', 'Antidiarrheals', 'Analgesics', 'Hematopoietic Growth Factors', 'Herbal products', 'Nutritional supplementation', 'Highly active antiretroviral therapy (HAART)', '5.3.2 Prohibited Therapies', 'Care should be taken to avoid therapies that may contribute or exacerbate GI or GU', 'toxicity from radiotherapy.', '5.3.3', 'Participation in Other Trials [if applicable]', 'Patients are prohibited from participating in any therapeutic intervention trial.', '5.4', 'Duration of Therapy', 'In the absence of treatment delays due to adverse event(s), treatment may continue as', 'specified in the above treatment modality sections or until one of the following criteria', 'applies:', 'Disease progression,', 'Intercurrent illness that prevents further administration of treatment,', 'Unacceptable adverse event(s), as described in Section 7', 'Patient decides to withdraw consent for participation in the study, or', \"General or specific changes in the patient's condition render the patient unacceptable\", 'for further treatment in the judgment of the investigator.', '6. TREATMENT MODIFICATIONS/MANAGEMENT', 'Not applicable', 'NRG-GU003', '27', 'Version Date: April 26, 2019']['7. ADVERSE EVENTS REPORTING REQUIREMENTS', '7.1', 'Protocol Agents', 'Not applicable', '7.2', 'Adverse Events and Serious Adverse Events (26-APR-2019)', '7.2.1', 'The descriptions and grading scales found in the revised NCI Common Terminology', 'Criteria for Adverse Events (CTCAE), version 4.0 will be utilized until March 31, 2018,', 'for all AE reporting, CTEP-AERS, and case report forms. CTCAE version 5.0 will be', 'utilized for CTEP-AERS reporting beginning April 1, 2018; all study case report forms', 'will continue to use CTCAE version 4.0. All appropriate treatment areas should have', 'access to a copy of CTCAE versions 4.0 and 5.0, which can be downloaded from the', 'CTEP web site', 'https://ctep.cancer.gov/protocolDevelopment/electronic applications/ctc.htm)', '7.2.2', 'Definition of an Adverse Event (AE)', 'Any untoward medical occurrence associated with the use of a drug in humans, whether', 'or not considered drug related. Therefore, an AE can be any unfavorable and unintended', 'sign (including an abnormal laboratory finding), symptom, or disease temporally', 'associated with the use of a medicinal (investigational) product, whether or not', 'considered related to the medicinal (investigational) product (attribution of unrelated,', 'unlikely, possible, probable, or definite). (International Conference on Harmonisation', '[ICH], E2A, E6).', 'For multi-modality trials, adverse event reporting encompasses all aspects of protocol', 'treatment including radiation therapy, surgery, device, and drug.', 'Due to the risk of intrauterine exposure of a fetus to potentially teratogenic agents, the', 'pregnancy of a study participant must be reported via CTEP-AERS in an expedited', 'manner.', '7.3', 'Expedited Reporting of Adverse Events', 'All serious adverse events that meet expedited reporting criteria defined in the reporting', 'table below will be reported via the CTEP Adverse Event Reporting System, CTEP-', 'AERS, accessed via the CTEP web site,', 'https://eapps-ctep.nci.nih.gov/ctepaers/pages/task?rand=1390853489613', 'Submitting a report via CTEP-AERS serves as notification to the NRG', 'Biostatistical/Data Management Center and satisfies NRG requirements for expedited', 'adverse event reporting.', 'CTEP-AERS provides a radiation therapy-only pathway for events experienced that', 'involve radiation therapy only. These events must be reported via the CTEP-AERS', 'radiation therapy-only pathway.', 'NRG-GU003', '28', 'Version Date: April 26, 2019']\n\n###\n\n", "completion": "END"}